Loading...
Alkermes plc
ALKS•NASDAQ
Healthcare
Biotechnology
$26.99
$0.86(3.28%)
Alkermes plc (ALKS) Financial Performance & Income Statement Overview
Review Alkermes plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-6.36%
↓ 6.36%
Operating Income Growth
1.57%
↑ 1.57%
Net Income Growth
3.18%
↑ 3.18%
Operating Cash Flow Growth
9.41%
↑ 9.41%
Operating Margin
25.84%
↑ 25.84%
Gross Margin
87.67%
↑ 87.67%
Net Profit Margin
23.30%
↑ 23.30%
ROE
25.41%
↑ 25.41%
ROIC
23.87%
↑ 23.87%
Alkermes plc (ALKS) Income Statement & Financial Overview
Review Alkermes plc's (ALKS) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $306.51M | $429.99M | $378.14M | $399.13M |
| Cost of Revenue | $0.00 | $62.12M | $63.10M | $61.47M |
| Gross Profit | $306.51M | $367.87M | $315.04M | $337.66M |
| Gross Profit Ratio | $1.00 | $0.86 | $0.83 | $0.85 |
| R&D Expenses | $71.82M | $56.67M | $59.89M | $59.65M |
| SG&A Expenses | $171.70M | $146.99M | $150.38M | $168.11M |
| Operating Expenses | $243.52M | $205.18M | $210.29M | $227.78M |
| Total Costs & Expenses | $292.72M | $267.30M | $273.39M | $289.25M |
| Interest Income | $10.14M | $11.40M | $10.92M | $10.73M |
| Interest Expense | $0.00 | $4.65M | $6.00M | $5.95M |
| Depreciation & Amortization | $0.00 | $6.85M | $6.97M | $6.66M |
| EBITDA | $13.79M | $181.38M | $123.20M | $129.33M |
| EBITDA Ratio | $0.04 | $0.42 | $0.33 | $0.32 |
| Operating Income | $13.79M | $162.69M | $104.76M | $109.88M |
| Operating Income Ratio | $0.04 | $0.38 | $0.28 | $0.28 |
| Other Income/Expenses (Net) | $11.70M | $7.20M | $5.47M | $6.84M |
| Income Before Tax | $25.49M | $169.89M | $110.23M | $116.72M |
| Income Before Tax Ratio | $0.08 | $0.40 | $0.29 | $0.29 |
| Income Tax Expense | $3.02M | $24.15M | $17.43M | $22.06M |
| Net Income | $22.46M | $146.50M | $92.38M | $91.36M |
| Net Income Ratio | $0.07 | $0.34 | $0.24 | $0.23 |
| EPS | $0.14 | $0.89 | $0.57 | $0.54 |
| Diluted EPS | $0.13 | $0.87 | $0.55 | $0.53 |
| Weighted Avg Shares Outstanding | $163.41M | $161.96M | $163.37M | $168.32M |
| Weighted Avg Shares Outstanding (Diluted) | $168.74M | $166.55M | $167.03M | $170.98M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan